Silver Is Getting P...
Health Care: Drugs
Biosante Pharmaceuticals Inc. (BPAX: NASDAQ)
$1.14 0.00 | 0.09%
05/20/13 - 12:04 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -27.72M | -51.61M | -46.20M | -47.53M |
| Operating Gains/Losses | 1.05M | 367.50K | 4.58K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 64.64K | 285.84K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -4.42M | 134.10K | 3.14M | -1.55M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 5.05M | 1.41M | 3.15M | 30.54M |
| Net Cash From Continuing Operations | -25.28M | -47.87M | -40.10M | -18.43M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -25.28M | -47.87M | -40.10M | -18.43M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 3.08K | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 3.03M |
| Purchases of Property, Plant & Equipment | -611.19K | -719.92K | -63.44K | -165.72K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -619.15K | -719.92K | -60.37K | 2.86M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 3.47M | 68.89M | 48.45M | 11.35M |
| Repayment of Long-Term Debt | 0.00 | -1.23M | 0.00 | 0.00 |
| Repurchase of Capital Stock | -658.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 22.32M |
| Net Cash From Financing Activities | 3.47M | 67.66M | 48.45M | 33.67M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -22.43M | 19.07M | 8.30M | 18.10M |
Portfolios with BPAX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorHot Biotech Stocks Traded b...
- UserSaveyn walter
- User2012_03
- Userwayne120
- ContributorBreakout Stocks Of The Week...
- UserDunDon1
- Contributor6 Drug Stocks Unworthy of B...
Latest BPAX Headlines from TheStreet
- The Worst Biotech CEO of 2012 Is... 12.07.12 | 09:12 am
- Your Vote Counts: Who Is the Worst Biotech CEO of 2012? 12.04.12 | 08:12 am
- The Next Big Thing In Biotech: Worst CEO Candidates
11.23.12 | 05:11 am - 4 Biotech Stocks Under $10 Soaring Higher 09.25.12 | 02:09 pm
- 5 Biotech Stocks Under $5 Blasting Off 08.16.12 | 03:08 pm
- BioSante Execs Use Failed Libigel To Keep Paychecks Rolling In 06.11.12 | 09:06 am
- Biosante Stock Gaps Down On Today's Open (BPAX) 06.01.12 | 09:06 am
- Biotech Twitter Mailbag: Gilead, Chelsea, Keryx, Onyx, BioSante, Dendreon 02.29.12 | 06:02 am
- Transocean, Netflix, BioSante Are Market Movers 02.27.12 | 05:02 pm
- Biotech Stock Mailbag: Vivus, Chelsea, BioCryst 02.17.12 | 05:02 am
Press Releases for BPAX
- Ceregene Reports Data From Parkinson's Disease Phase 2b Study - PR Newswire 04.19.13 | 02:04 pm
- BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders To Vote “FOR” Proposed Merger With ANI Pharmaceuticals, Inc. - Business Wire 03.19.13 | 09:03 am
- BioSante Pharmaceuticals Announces Adjournment Of Its Stockholders Meeting Until April 12, 2013 - Business Wire 03.15.13 | 04:03 pm
- Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial - PR Newswire 03.13.13 | 07:03 am
- Glass, Lewis & Co., LLC Recommends Vote “FOR” BioSante/ANI Merger - Business Wire 03.04.13 | 09:03 am
- BioSante Pharmaceuticals Provides Merger Update And Reports 2012 Financial Results - Business Wire 03.01.13 | 09:03 am
- Leading Independent Proxy Advisory Firm ISS Joins Egan-Jones In Recommending “FOR” BioSante/ANI Merger - Business Wire 02.26.13 | 09:02 am
- Egan-Jones Proxy Services Recommends Stockholders Vote “FOR” BioSante And ANI Merger - Business Wire 02.19.13 | 09:02 am
- BioSante Pharmaceuticals And ANI Pharmaceuticals Announce Special Meetings Of Stockholders To Consider Proposed Merger - Business Wire 01.22.13 | 04:01 pm
- BioSante Pharmaceuticals Reports Third Quarter Financial Results And Merger Update - Business Wire 11.08.12 | 04:11 pm
Partner Headlines for BPAX
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- 5 BioPharmas To Watch For Wednesday, September 5 - Seeking Alpha 09.05.12 | 09:09 am
- Healthcare Biz Recap: Complete Genomics CUTS Costs, Abbott Labs Teams Up - Wall St. Cheat Sheet 06.06.12 | 08:06 am
- Alimera Sciences: An Upcoming Catalyst Should Make For A Nice Stock Gain - Seeking Alpha 03.26.12 | 09:03 am
- Bio-Pharma Watch List: 2 Week Report Card - Seeking Alpha 03.12.12 | 09:03 am
- What BioSante's Balance Sheet Says About Future R&D - Seeking Alpha 03.01.12 | 08:03 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- 3 Biotechs Hopefully To Get Rich Or Die Trying - Seeking Alpha 01.04.12 | 08:01 am
- Singular Research Drops Coverage on BioSante Pharma After LibGel Results - Benzinga 12.16.11 | 04:12 pm
- Singular Research Reiterates BioSante Pharmaceuticals Buy, Maintains PT - Benzinga 12.13.11 | 01:12 pm
